Trial Profile

A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
08 Aug 2023 Planned End Date changed from 1 Sep 2021 to 1 Dec 2023.
27 Apr 2023 Results assessing long-term safety and efficacy of continuous subcutaneous apomorphine infusion (CSAI) for motor fluctuations in Parkinson's disease (PD) patients treated in United States (US) settings, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com